Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Inclusion Criteria: * Glycogenosis type 1b confirmed by biochemical analyzes and / or genetic analysis. These patients with Glycogenosis must have had a liver transplant * Alternatively, G6PC3 deficiency confirmed by genetic analysis * Age 1 to 18 years old female or male * Informed consent signed by the recipient and / or parents / assigns. * Information and agreement of the referring medical team. * A Negative Blood Pregnancy Test at the time of screening and a negative urinary pregnancy test at Day 1 of the protocol are required for female with child bearing potential. * Sexually active patients should use an effective method of contraception throughout the duration of the study and up to 7 days after the last dose of Empaglifozine. (The combination of a hormonal method and a barrier method; Two barrier methods, the male condom being one of these two methods;Use intrauterine device or tubal ligation;-A total sex abstinence.) Exclusion Criteria: * Presence of advanced fibrosis (Metavir F4) or cirrhosis. * Impossibility of long-term and / or non-compliance monitoring. * Other medical problems which, in the opinion of the physicians in charge of the patient, would constitute a contraindication to the procedure. * Sexually active patients who do not consent to use effective contraception during the study.